This produces a colossal financial burden especially in a country like India. As a consequence, there are irregular follow-ups, delay in therapy, increased disease burden and a resultant alarming multi-drug resistance. To overcome these problems, in April 2002 WHO recommended the usage of total lymphocyte count (TLC) less than 1000 to 1200 cells/mm 3 as indication to start HAART in resource-limited settings. [6] There are however conflicting reports as to whether TLC is a reliable substitution for CD4 count. In 2013, WHO revised its guidelines and recommended therapy to patients with severe or advanced HIV clinical disease (WHO clinical stage 3
INTRODUCTIONThe burden of HIV remains high for patients and their families especially in resource-limited settings. It is estimated that 40 million people with human immunodeficiency virus (HIV) reside in resource-limited settings. Among them it is reported that 6 million require highly active anti retroviral therapy (HAART). [1] In India alone, there are 2-3 million people infected with HIV. [2] Ideally the WHO recommends regular combined immunological and virological monitoring for all HIV-infected patients. [3] Analysis for viral loads and CD4 counts require not only sophisticated equipment, but in addition, highly skilled